Update on management of heart failure with preserved ejection fraction

Current Opinion in Cardiology

Volumn 30, Issue 2, 2015, Pages 173-178

  Pellicori, Pierpaolo ^a   Cleland, John G F ^b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Heart failure with preserved ejection fraction; NT proBNP; Review; Treatment

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; BIOLOGICAL MARKER; ENALAPRIL; NATRIURETIC FACTOR; NIFEDIPINE; VALSARTAN;

BLOOD LEVEL; CARDIOVASCULAR RISK; DIAGNOSTIC PROCEDURE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; LIFE EXPECTANCY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SODIUM RESTRICTION;

EID: 84927727700     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000152     Document Type: Review

References (39)

1. vanRiet EE, Hoes AW, Limburg A, et al. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014; 16:772-777. Elderly primary care patients with breathlessness on exertion often have undiagnosed heart failure, mainly with preserved ejection fraction.
2. Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3:588-595. This study showed that HFPEF patients may have markedly abnormal haemodynamic responses during exercise.
3. Dorfs S, Zeh W, Hochholzer W, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J 2014; 35:3103-3112.
4. Kraigher-Krainer E, Shah AM, Gupta DK, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63:447-456.
5. Pellicori P, Kallvikbacka-Bennett A, Khaleva O, et al. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: Does it improve diagnosis and risk stratification? Int J Cardiovasc Imaging 2014; 30:69-79. Abnormal long-axis systolic function is often identified in patients with HFPEF.
6. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014; 2:113-122.
7. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2014; 11:507-515.
8. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62:263-271.
9. Banerjee P, Clark AL, Nikitin N, et al. Diastolic heart failure. Paroxysmal or chronic? Eur J Heart Fail 2004; 6:427-431.
10. Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011; 124:2491-2501.
11. Shah AM, Claggett B, Sweitzer NK, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: Findings from the echocardiographic study of the Treatment Of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 2014; 7:740-751.
12. Cleland JG, Pellicori P. Defining diastolic heart failure and identifying effective therapies. JAMA 2013; 309:825-826.
13. Cleland JG, Taylor J, Tendera M. Prognosis in heart failure with a normal ejection fraction. N Engl J Med 2007; 357:829-830.
14. Cleland JG, Taylor J, Freemantle N, et al. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: A report from the PEP-CHF study. Eur J Heart Fail 2012; 14:487-494.
15. vanVeldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61:1498-1506.
16. Pellicori P, Hutchinson K, Clark AL, et al. Does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? J Am Coll Cardiol 2014; 64:1535.
17. Pellicori P, Zhang J, Lukaschuk E, et al. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. Eur Heart J 2014. [Epub ahead of print].
18. Pellicori P, Kallvikbacka-Bennett A, Zhang J, et al. Revisiting a classical clinical sign: jugular venous ultrasound. Int J Cardiol 2014; 170:364-370.
19. Pellicori P, Carubelli V, Zhang J, et al. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 2013; 6:16-28.
20. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260-269.
21. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59:998-1005.
22. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50:768-777.
23. Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 2013; 15:604-613.
24. Adabag S, Smith LG, Anand IS, et al. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail 2012; 18:749-754.
25. Henkel DM, Redfield MM, Weston SA, et al. Death in heart failure: A community perspective. Circ Heart Fail 2008; 1:91-97.
26. Cleland JG, Pellicori P, Dierckx R. Clinical trials in patients with heart failure and preserved left ventricular ejection fraction. Heart Fail Clin 2014; 10:511- 523.
27. Anand IS, Rector TS, Cleland JG, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: Findings from the I-PRESERVE trial. Circ Heart Fail 2011; 4:569- 577.
28. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370:1383-1392. Some patients with HFPEF might benefit from spironolactone, particularly when they have elevated plasma natriuretic peptides.
29. Cleland JG, Tendera M, Adamus J, et al., PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345.
30. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362:777-781.
31. Yip GW, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: A randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008; 94:573-580.
32. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
33. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
34. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50:401-414.
35. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993-1004.
36. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012; 380:1387-1395.
37. Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): A randomized, double-blind, placebocontrolled, single-dose study. Chest 2014; 146:1274-1285.
38. Pieske B, Butler J, Filippatos G, et al. Rationale and design of the Soluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 2014; 16:1026-1038.
39. Dai DF, Hsieh EJ, Chen T, et al. Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrialtargeted peptides. Circ Heart Fail 2013; 6:1067-1076.